Quantcast

Novartis Announces Phase II Preliminary Results Of GEOMETRY Mono-1 Trial


Shutterstock photo


(RTTNews.com) - Novartis announced Phase II preliminary results of the GEOMETRY mono-1 clinical trial of investigational MET inhibitor capmatinib (INC280) in 94 adult patients with advanced non-small cell lung cancer or NSCLC harboring MET exon-14 skipping mutations.

The GEOMETRY mono-1 study showed an overall response rate (ORR) of 72.0% (95% CI: 50.6-87.9) in treatment-naive patients and 39.1% (95% CI: 27.6-51.6) in previously treated patients. ORR was assessed by blinded independent review committee (BIRC). Adverse events (AEs) were consistent with previously reported data and no new safety signals were observed.

"These preliminary findings reveal the potential of capmatinib in MET exon-14 skipping mutated NSCLC patients. Compared to the previously treated patient groups, the primary advantage in terms of overall response rate reported in treatment-naive patients highlights the clinical relevance for an earlier diagnostic testing and prompt treatment of this challenging patient population," said Juergen Wolf, MD, University Hospital Cologne.

NSCLC is the most common type of lung cancer, impacting more than 2 million people per year. Approximately 3-4% of all patients with NSCLC have an identified MET mutation. Though rare, this mutation is an indicator of especially poor prognosis and there is currently no approved therapy designed to target this mutation.


Read the original article on RTTNews (http://www.rttnews.com/2945349/novartis-announces-phase-ii-preliminary-results-of-geometry-mono-1-trial.aspx)


For comments and feedback: contact editorial@rttnews.com




This article appears in: Stocks
Referenced Symbols: NVS



More from RTT News

Subscribe






See All RTT news











Research Brokers before you trade

Want to trade FX?